Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Alliance / A022106

Trial Overview

Official Title

PHASE II/III SECOND-LINE NABPLAGEM VS. NAB-PACLITAXEL/GEMCITABINE IN BRCA1/2 OR PALB2 MUTANT METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PLATINUM)

Study Purpose

To evaluate and compare overall response rate (ORR) in patients with BRCA1/2 or PALB2 mutant pancreas cancer whose disease has progressed on front-line FOLFIRINOX treated with NABPLAGEM = nab-paclitaxel, gemcitabine, and cisplatin (arm 1) versus nab-paclitaxel and gemcitabine (arm 2)

Diagnosis

Pancreatic cancer

Eligibility

Histologic documentation of metastatic pancreatic adenocarcinoma, adenosquamous carcinoma, carcinoma or acinar carcinoma -Pathogenic BRCA1/2 or PALB2 mutation (somatic or germline);

 

Intervention

Arm 1: Nab-paclitaxel 100 mg/m2 + cisplatin 25 mg/m2 + gemcitabine 800 mg/m2 on days 1 and 15

Arm 2: Nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 on days 1 and 15

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT06115499?term=A022106&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
A022106